Proactive - Interviews for investors

Proactive - Interviews for investors

Download on the App Store

All Proactive - Interviews for investors episodes

  • Saturna Capital analyst flags global AI opportunities and risks of soaring investment
    Saturna Capital senior investment analyst and portfolio manager Levi Stewart Zurbrugg talked with Proactive's Stephen Gunnion about global equity opportunities, the international AI supply chain, rising interest rates and the financial risks of surging AI infrastructure spending.
    Zurbrugg explained why investors should look beyond US markets, highlighting opportunities in Taiwan's semiconductor industry, Dutch lithography technology, Korean memory manufacturing and Japanese optical fibre suppliers.
    He also discussed improving global manufacturing conditions and how rising interest rates can affect equities, depending on the underlying strength of the economy.
    Turning to AI investment, Zurbrugg warned that rising depreciation costs from hyperscaler capital expenditure could significantly offset S&P 500 earnings growth in 2027 and 2028. He also highlighted growing reliance on external financing and the importance of monitoring corporate debt and credit conditions.
    The interview explores Saturna's Islamic investment screening approach, which limits exposure to companies with debt exceeding 30% of market capitalisation.
    Zurbrugg also explains why international diversification, exemplified in the Saturna Global Equity ETF, could offer investors opportunities as the AI investment cycle evolves.
    For more interviews and financial market insights, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications to stay updated on future content.
    Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy
    #SaturnaCapital #GlobalEquities #AIInvesting #GlobalInvesting #StockMarket #ArtificialIntelligence #AIInfrastructure #InvestmentStrategy #EquityMarkets #InterestRates #MarketOutlook #PortfolioManagement #HalalInvesting #IndustrialStocks #ProactiveInvestors
    8 min
  • Sprott Asset Management's Jacob White on uranium stocks sell-off and the case for a recovery
    Sprott Asset Management Director of ETF Product Management Jacob White talked with Proactive's Stephen Gunnion about the sharp sell-off in uranium mining stocks, the disconnect with physical uranium prices and the potential catalysts for a recovery.
    White explained that uranium equities have come under pressure despite spot prices rising more than 10% year to date to above US$90 per pound, while long-term contract prices have reached fresh highs.
    He attributed the weakness largely to broader market volatility and pressure on risk assets rather than any deterioration in uranium fundamentals.
    The interview also explores nuclear power's long-term growth prospects, with White highlighting energy security, reliable baseload electricity and rising demand from data centres as important drivers.
    On the supply side, he pointed to a continuing uranium deficit, reduced production guidance from Cameco and tightening utility inventories.
    White also discussed the prospect of increased utility contracting as buyers seek to secure future supplies, alongside new reactor construction, restarts and plant-life extensions.
    He explained why improving market liquidity could help uranium mining shares reconnect with the strength of the physical market.
    For more interviews and market insights, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications to stay updated on future content.
    Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy
    #Uranium #UraniumStocks #UraniumMining #UraniumPrices #NuclearEnergy #NuclearPower #UraniumInvesting #UraniumMarket #EnergySecurity #MiningStocks #SprottAssetManagement #Commodities #EnergyInvesting #Cameco #ProactiveInvestors
    7 min
  • XanaMIA results: What's next for Actinogen Medical?
    Actinogen Medical Ltd CEO Dr Steven Gourlay talked with Proactive about the topline results from the company's XanaMIA clinical trial, which evaluated its investigational Alzheimer's disease treatment Xanamem. The study revealed encouraging signs of disease slowing in patients aged over 75, although the primary endpoint was not achieved across the overall trial population.
    Gourlay highlighted a statistically significant difference in complete disease stabilisation among older participants, with 40% of patients receiving Xanamem showing no disease progression compared with 22% in the placebo group.
    The CEO also discussed the reported 30% slowing of Alzheimer's disease progression among patients older than 75, comparing the results with those observed for intravenous antibody therapies.
    Gourlay explained why the stronger response in older patients could be consistent with Xanamem's mechanism of action, which targets an enzyme involved in cortisol production in the brain.
    Looking ahead, Actinogen Medical is continuing its open-label extension study, with an expanded dataset expected in early 2027. Gourlay discussed the encouraging preliminary observations from 29 participants and the company's plans to assess results from at least 100 patients.
    With A$18.9 million in cash, Actinogen Medical also intends to engage with potential pharmaceutical development partners and regulators before committing further expenditure to a Phase 3 programme.
    Watch the full interview to hear Dr Steven Gourlay explain the XanaMIA results, the opportunity in older Alzheimer's patients and the potential next steps for Xanamem.
    For more biotechnology, healthcare and ASX company interviews, visit Proactive's YouTube channel. Give this video a like, subscribe to the channel and enable notifications so you don't miss future updates.
    #ActinogenMedical #AlzheimersDisease #Xanamem #XanaMIA #AlzheimersResearch #ClinicalTrials #Biotechnology #DrugDevelopment #ASXACW #HealthcareStocks #Phase3Trials #Neuroscience #ProactiveInvestors
    6 min
  • Parbo Resources uncovers new greenstone belt at Mount Padbury
    Parbo Resources (ASX:PRB) CEO Tim Campbell talked with Proactive's Stephen Gunnion about maiden reverse circulation (RC) drilling results at the Mount Padbury gold project, where drilling has confirmed greenstone beneath previously mapped granite at the GoldenEye prospect, from just 44 metres below surface.
    Since listing on the ASX in September, Parbo has moved quickly to advance exploration across its two main projects: gold-focused Mount Padbury and the Bryah Basin copper-gold project.
    Campbell described the discovery as an entirely new potential greenstone belt, highlighting the significance of the geological findings across the company's 760-square-kilometre Mount Padbury tenure.
    The interview also explored results from the Goldfinger prospect, where drilling intersected sulphide-bearing breccia and alteration associated with the Plutonic structure. Evidence of six phases of fluid flow points to a potentially significant mineralising system, with around 60 kilometres of comparable, largely untested targets along the structure.
    With initial assay results still pending, Campbell outlined plans for further gravity and magnetic surveys to prioritise drilling.
    He also updated investors on the Brian's Mill gold prospect in the Bryah Basin, where assays are awaited, and plans for RC drilling at the Naraku copper-gold prospect.
    Watch the full interview to hear about Parbo's exploration strategy and the next steps across its projects.
    For more interviews and updates from ASX-listed companies, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications to stay informed about future content.
    Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy
    #ParboResources #GoldExploration #ASX #MountPadbury #BryahBasin #GoldDrilling #CopperExploration #MineralExploration #RCDrilling #GoldMining #CopperGold #MiningStocks #ASXStocks #JuniorMining #ProactiveInvestors
    6 min
  • Arrow Exploration CEO on Icaco success, record production and next drilling targets
    Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) CEO Marshall Abbott talked with Proactive's Stephen Gunnion about the company's latest drilling success at Icaco in Colombia, where the IC-HZ9 well has exceeded production expectations and helped lift corporate output above 7,000 barrels of oil equivalent per day.
    Abbott highlighted the well's strong performance and reserves potential, explaining how a specialist monobore design with cemented casing and targeted perforations is helping optimise production.
    Although initial output reached around 3,000 barrels per day, Arrow is managing flow rates to maximise ultimate reservoir recovery rather than short-term production.
    Looking ahead, the company has identified six additional drilling locations at Icaco, while the recently spudded IC-HZ10 is targeting the Ubaque formation. Abbott outlined the potential for further reserves growth and rapid well payback under Colombia's fiscal regime.
    The interview also covers Arrow's cash position of more than US$35 million and progress towards securing an extension to the Tapir block contract, a key priority for its longer-term growth plans.
    For more interviews and updates from companies operating across the energy and natural resources sectors, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications to stay informed about future content.
    Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy
    #ArrowExploration #OilAndGas #ColombiaOil #MarshallAbbott #Icaco #OilProduction #OilExploration #EnergyInvesting #Drilling #Ubaque #TapirBlock #EnergyStocks #ProactiveInvestors
    5 min
  • JURY ETF builds investor interest with its human rights-focused approach
    Jonny White, sales & client manager at Ethical Screening and senior advisor at The Justice Company, talked with Proactive's Stephen Gunnion about the first six months of the JURY Global High Dividend UCITS ETF (LSE:JURY), growing investor interest, and its first portfolio rebalance.
    White said the fund has attracted interest from individual and institutional investors across the UK, Europe, the Middle East and North America.
    Unlike broader environmental, social and governance (ESG) strategies, JURY focuses specifically on human rights, using an approved-or-excluded screening process to assess companies against defined criteria.
    White explained how the first portfolio rebalance involved reviewing companies for potential links to human rights violations, occupation, apartheid and other activities. The process combines ongoing research with engagement, allowing companies to respond to allegations before assessments are finalised.
    He also outlined how Ethical Screening is refining its methodology through additional research sources and engagement with non-governmental organisations and other institutions.
    Looking ahead, White sees scope for further investor interest as people increasingly seek greater transparency over where their money is invested and how companies are assessed.
    Watch the full interview to hear more about JURY's screening approach, portfolio development and the outlook for human rights-focused investing.
    For more interviews and updates from companies across the investment sector, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel and enable notifications so you never miss future content.
    Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy
    #EthicalScreening #ETFInvesting #ResponsibleInvesting #ESGInvesting #HumanRights #SustainableInvesting #InvestmentNews #ProactiveInvestors
    9 min
  • Nova Minerals advances Alaska antimony project with $23.9m in Department of War funding received
    Nova Minerals Limited CEO Christopher Gerteisen joined Steve Darling from Proactive to discuss the company's financial and operational results for the quarter ended September 30, 2026, highlighting continued progress at its flagship Estelle Gold and Critical Minerals Project in Alaska and plans to establish a vertically integrated US domestic antimony supply chain.
    The company continues to advance engineering, metallurgical test work, equipment procurement and site preparations as it works towards its targeted 2027 production timeline. By the end of the quarter, approximately 500 tons of processing and refining equipment had been delivered to Port MacKenzie, with early earthworks also underway.
    Nova Minerals also provided an update on its US$43.4 million Department of War award. As of September 30, approximately US$23.9 million had been received. A further programme milestone was achieved after quarter-end, with an additional US$5 million invoiced. The remaining funding is subject to the completion of applicable programme milestones and is expected to be received by the end of fiscal year 2027.
    On the exploration and development front, the company completed drilling at its Styx and Stibium prospects and has collected approximately 100 tons of antimony-bearing material to date. The material is intended to provide initial feedstock for pilot-scale processing.
    A significant regulatory milestone was also achieved, with Nova receiving all final approvals from the Alaska Department of Natural Resources for its integrated, three-year antimony pilot-scale development programme.
    The approvals cover the planned extraction of ore at the Styx and Stibium prospects, ore sorting and processing at Whiskey Bravo, and downstream processing and refining at Port MacKenzie.
    The integrated approach is designed to advance the company's ambition of developing a domestic US antimony supply chain, connecting mining, processing and refining operations in Alaska.
    #proactiveinvestors #novamineralslimited #nasdq #nva #asx #nva #Antimony #CriticalMinerals #Gold #Alaska #EstelleProject #DepartmentOfWar #USMining #MineralProcessing #Mining
    7 min
  • Custom Health CEO targets profitability by late 2027 after 220% revenue surge
    Custom Health Holdings Inc (TSX:CHLT) CEO Shane Bishop talked with Proactive's Stephen Gunnion about the company's third-quarter financial results, which saw revenue jump 220% to $14.4 million, alongside its acquisition strategy, smart medication technology and plans to improve margins and work towards profitability by late 2027.
    Bishop explained that the significant increase in revenue largely reflected the acquisition of InnovativeRx, which aligns with Custom Health's strategy of acquiring pharmacies in geographical markets where it already has payer relationships supporting in-home technology and clinical services.
    "We have seen organic growth on top of the baseline revenue that we brought in due to that acquisition," Bishop said, highlighting the company's progress in building revenue beyond its acquired pharmacy operations.
    The discussion also covered Custom Health's decision to bring Spencer Health Solutions and its smart medication dispensing technology fully in-house. Bishop outlined how controlling device costs, consolidating support functions and owning intellectual property could support future margin expansion.
    He also emphasised the importance of retaining control over patient data as the company looks to integrate artificial intelligence and demonstrate improved outcomes and returns for payers.
    Turning to the company's partnership with BKC Pain Specialists, Bishop highlighted encouraging medication adherence results among complex patient populations. He also discussed how patient-reported outcomes are supporting Custom Health's clinical services and SaaS technology revenue alongside its pharmacy business, potentially creating opportunities to engage larger healthcare providers.
    Looking ahead, Bishop identified continued acquisitions, revenue growth, cost control and access to capital markets as priorities. The company is targeting the back end of 2027 for its profitability ambitions, with execution and margin expansion central to that objective.
    Visit Proactive's YouTube channel for more interviews and updates on publicly traded companies. Don't forget to like this video, subscribe to the channel and enable notifications to stay informed about future content.
    Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy
    #CustomHealth #ShaneBishop #HealthcareTechnology #InnovativeRx #SpencerHealthSolutions #DigitalHealth #MedicationAdherence #PharmacyAcquisitions #HealthcareInnovation #RevenueGrowth #SmartMedicationDispenser #PatientOutcomes #HealthTech #ProactiveInvestors
    5 min
  • Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans
    Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and preparations for a Phase 3 trial.
    L’Huillier explained how the Regenerative Medicine Advanced Therapy designation will enable closer engagement with the FDA on clinical development, manufacturing and potential accelerated approval pathways.
    He highlighted updated results showing 87% overall survival and 71% progression-free survival among patients receiving the second-generation iSCIB1+ treatment, now known as inzi. More than one-third achieved complete responses, with L’Huillier pointing to the durability of results.
    The interview also explores progress with Modi-1, where almost 50% of patients in the renal cancer cohort demonstrated strong vaccine-related immune responses.
    L’Huillier provided updates on Scancell's ImmunoBody and GlyMab platforms, including developments involving Genmab, before discussing the proposed reverse merger with Neuphoria and associated funding.
    The transaction remains targeted for completion by the end of 2026 or early 2027, supporting plans to advance inzi into Phase 3 development.
    For more interviews and updates from listed companies, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications for future content.
    Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy
    #Scancell #ScancellHoldings #Melanoma #CancerImmunotherapy #Biotech #FDA #RMAT #ClinicalTrials #Phase3Trial #Oncology #CancerResearch #Immunotherapy #BiotechStocks #HealthcareInvesting #Modi1 #Neuphoria #Nasdaq #ProactiveInvestors
    8 min
  • CAP-XX CEO highlights record orders, defence demand and FY2027 growth plans
    CAP-XX Limited (AIM:CPX) CEO Lars Stegmann talked with Proactive's Stephen Gunnion about improving financial performance, accelerating demand for supercapacitors and plans to achieve sustainable break-even.
    The company reported an 11% increase in FY2026 revenue, a 33% reduction in EBITDA losses and 35% growth in new orders. Momentum has continued into FY2027, with first-quarter orders up 66% year-on-year and the backlog reaching A$4.2 million.
    Stegmann highlighted growing demand from aerospace and defence customers, alongside opportunities across the company's wider product portfolio. He also discussed distribution and technology partnerships that provide access to around 900 additional salespeople worldwide, expanding CAP-XX's global reach.
    The interview explores the A$4.4 million capital raise and R&D tax incentives, which will support Australian research, development and manufacturing improvements.
    Looking ahead, Stegmann identified the planned relocation of manufacturing from Malaysia to Australia as a key milestone, strengthening control over intellectual property, production and quality.
    He also explained why the priority is not simply reaching break-even, but sustaining profitability while continuing to grow.
    For more company interviews and market updates, visit Proactive's YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications to stay informed about future content.
    Read Proactive’s Editorial Policy here: https://www.proactiveinvestors.com/pages/editorialPolicy
    #CAPXX #Supercapacitors #InvestorNews #CAPXXLimited #LarsStegmann #EnergyStorage #SupercapacitorTechnology #AerospaceAndDefence #Manufacturing #RevenueGrowth #OrderGrowth #AustralianManufacturing #ResearchAndDevelopment #FY2027 #ProactiveInvestors
    8 min